Pharmaceuticals - D-A-CH

D-A-CH

The Pharmaceuticals market in D-A-CH is expected to achieve a revenue of US$50.28bn in 2024.
Among the various markets, Oncology Drugs is projected to be the largest, with a market volume of US$9.86bn in the same year.
Looking ahead, the industry is anticipated to experience a steady growth rate, with a compound annual growth rate (CAGR 2024-2028) of 6.44%.
This growth will result in a market volume of approximately US$64.54bn by 2028.
In terms of global comparison, United States is expected to generate the highest revenue, reaching US$636.90bn in 2024.
Germany's pharmaceutical market is experiencing a surge in research and development, with a particular focus on innovative therapies and precision medicine.

Key regions: United States, China, Germany, Japan, Europe

Definition:
The Pharmaceuticals market covers remedies used to cure, treat, prevent, and diagnose diseases. These small molecule drugs or biologic medical products may be called drugs, medications, or medicines. Prescription drugs and over-the-counter (OTC) drugs are both included. Depending on the regulations in each country, these products are provided by pharmacies, hospitals, physicians, and/or drug stores, and/or they can be bought elsewhere. They may be administered in the form of pills, capsules, gels, ointments, injections, infusions, lozenges, or aerosols/sprays.

Structure:
The market is subdivided into Oncology Drugs, Anti-Diabetes Drugs, Anti-Rheumatic Drugs, Vaccines, Dermatological Drugs, Antiviral Drugs, Immunosuppressants, Bronchodilator Drugs, Sensory Organ Drugs, Anti-Hypertensive Drugs, Anti-Coagulants, Anti-Fibrinolytic Drugs, Multiple Sclerosis Drugs, Lipid-Lowering Agents and Other Pharmaceuticals. The Pharmaceuticals market is organized in markets that cover drugs used in specific medical fields, i.e., medicines for a specific disesase or a certain type of medicine. They include original brands, biosimilars, generics, and orphan drugs.The Oncology Drugs market covers pharmaceutical products specifically developed for the treatment and management of various cancers. The Anti-Diabetes Drugs market covers medications designed to manage blood glucose levels and improve insulin sensitivity in individuals with diabetes. The market Anti-Rheumatic Drugs includes pharmaceuticals specifically developed to alleviate symptoms, reduce inflammation, and modify the progression of rheumatic diseases. The Dermatological Drugs market covers pharmaceuticals formulated to treat and manage a wide range of skin conditions such as eczema, acne, and rosacea. The Antiviral Drugs market includes medications designed to treat viral infections and reducing the severity and duration of symptoms. The Immunosuppressants market covers pharmaceuticals that suppress the immune system's activity. The Bronchodilator Drugs market covers pharmaceuticals designed to relax and widen the airways in the lungs. The Sensory Organ Drugs market covers pharmaceuticals targeting the treatment of disorders and conditions affecting sensory organs such as the eyes, ears and nose. The Anti-hypertensive Drugs market covers pharmaceuticals designed to lower blood pressure levels. The Anti-Coagulants Drugs market covers pharmaceuticals developed to prevent the formation of blood clots or to dissolve existing clots. The Anti-Fibrinolytics Drugs market covers pharmaceuticals designed to inhibit the breakdown of blood clots. The Multiple Sclerosis Drugs market covers pharmaceuticals aimed at managing and modifying the course of multiple sclerosis. The Lipid-Lowering Agents market covers pharmaceuticals developed to reduce levels of cholesterol and other lipids in the blood. The Other Pharmaceuticals market provides information on additional specialties that are not covered by the main markets.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novartis, Roche, Pfizer, Merck & Co, Johnson & Johnson, AbbVie, Sanofi.

Market

Region

Region comparison

Currency

Analyst Opinion

The Pharmaceuticals market in D-A-CH, consisting of Germany, Austria, and Switzerland, is one of the largest markets in Europe.

Customer preferences: The pharmaceuticals market in D-A-CH is driven by the aging population, increasing healthcare expenditure, and a high incidence of chronic diseases. Customers in this region prefer high-quality medications and are willing to pay a premium for them. They also value personalized medicine and are increasingly interested in alternative therapies.

Trends in the market: In Germany, the pharmaceuticals market is expected to grow due to an increase in research and development activities and a rise in the number of clinical trials. Austria is experiencing a trend towards digitalization in healthcare, with an increasing number of telemedicine services and e-prescriptions. Switzerland is seeing a rise in the demand for specialty drugs, particularly in the areas of oncology and rare diseases.

Local special circumstances: Germany has a strong generics market, with many customers opting for cheaper alternatives to brand-name drugs. Austria has a relatively small domestic market, leading to a high level of imports and exports. Switzerland has a unique regulatory environment, with strict pricing controls and a focus on innovation.

Underlying macroeconomic factors: The pharmaceuticals market in D-A-CH is influenced by various macroeconomic factors, such as government policies, healthcare spending, and economic growth. The aging population and increasing healthcare expenditure are major drivers of the market. Additionally, the region's strong economy and high level of innovation contribute to the growth of the pharmaceuticals industry.In conclusion, the pharmaceuticals market in D-A-CH is a complex and dynamic industry that is shaped by various factors. Customer preferences, trends in the market, local special circumstances, and underlying macroeconomic factors all play a role in the development of the industry. With an aging population and increasing healthcare expenditure, the pharmaceuticals market in D-A-CH is expected to continue to grow in the coming years.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.